A new class action lawsuit against GlaxoSmithKline, the manufacturer of Fluorofloxacin, claims that the company knowingly sells a toxic chemical known as fluoroquinolones to unknowing pharmacies. As many as six deaths a year are directly attributed to this chemical, which is known as “bacterial” antifungal. According to the complaint filed in state court in California, GlaxoSmithKline should have known that its products contain Fluoroquinolones because it has shown in studies that the chemical produces byproducts that are carcinogenic in nature.
The complaint also claims that GlaxoSmithKline has refused to show evidence that Fluoroquinolones has no effect on patients other than allergic reactions.
This is despite the fact that the FDA has approved Fluoroquinolones for sale. Further, the FDA itself is currently conducting a study on the long term health effects of Fluoroquinolones and is expected to complete it by 2021. It is also currently the subject of a class action lawsuit that was initiated by attorneys general in several states. This lawsuit is currently being handled in Federal Court in Maryland.
The primary plaintiffs in the lawsuit are the children of one woman who died from untreated lung disease.
Another member of this same family developed what is known as non-productive lung syndrome after taking Fluoroquinolones. A class of direct victims in this lawsuit include many adults who were diagnosed with liver cancer, kidney cancer, gastrointestinal cancer, laryngeal cancer, esophageal cancer, and nasal polyps. Several other plaintiffs are related to mesothelioma, the most deadly type of cancer.
There are two class action lawsuits currently before the courts dealing with this chemical, and both of them are expected to be resolved fairly soon.
One suit was brought against GlaxoSmithKline by a group of former employees who claimed that the drug had caused them to develop a host of serious medical conditions. These suits were only recently approved for class action participation, but the results of those suits will almost certainly spell out a victory for the plaintiffs.
A secondary lawsuit, brought against GlaxoSmithKline by a group of women claiming that the drug had led to breast cancer and other serious ailments.
This second lawsuit is currently awaiting court approval. As with the first lawsuit, a large majority of the plaintiffs in these cases are expected to receive financial compensation. There is also a possibility that additional plaintiffs will be added to the lawsuit as the case progresses.
Fluoronoa can only be found in prescription medications. This is because it acts upon the immune system by altering the function of a number of genes. Once these genes are affected, the immune system is no longer capable of fighting off infections. In addition, there is a correlation between liver cancer and regular use of Fluoronoa. This correlation was discovered after a study was conducted in Japan. After studying both men and women, it was found that over two thirds of the participants who took Fluoronoa showed a high risk of liver cancer.
A common side effect of Fluoronoa is the formation of bone pain and tenderness.
There is also an increased risk of gout and high blood pressure. There have been numerous studies performed by independent investigators that directly correlate these affects to Fluoronoa usage.
There is currently no known safe dosage of Fluoronoa. However, there have been many studies done on animals that do not display any negative affects from such high doses. The company has continually offered information to the FDA pertaining to the safe amount of exposure for employees. Without having direct access to all of this information, it is impossible to determine the true scope of the effects that can occur.